Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths14.11.2025 - 2How stripping diversity, equity and inclusion from health care may make Americans sicker21.12.2025
- 3Space station changes command, setting stage for Crew 11 departure12.01.2026
- 410 Asian Countries Perfect for Solo Female Travelers16.12.2025
- 5Coalition led by Iraqi PM al-Sudani wins parliamentary elections12.11.2025
- Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- Newly Built Sichuan Hydropower Bridge Collapses Into River Months After Opening
- From Loner to Force to be reckoned with: Individual Accounts of Change
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- Over 250,000 cases of shredded cheese recalled over possible metal fragments
- Presenting Nintendo's New Pastel Bliss Con Tones for Switch Gamers: 3 Smart Choices
- Nestlé recalls infant formula in 49 countries. See list.
- Hoist Your Style: Famous Hairdos for Ladies
